Ask AI
ProCE Banner Events

Share

Systemic Treatment for Hepatobiliary Cancers in First and Later Lines: Applying the Latest Data (PRIVATE EVENT)

Interact with an expert during a 1-hour, CME/CNE/CPE-certified live meeting examining recent advances and current best practices in treatment for hepatocellular carcinoma and biliary tract cancers. Register today!

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Registration not open

Credits Available

1.0

Who Should Attend

This educational program is intended for hepatologists, medical oncologists, radiation oncologists, surgical oncologists, nurses, pharmacists, and other healthcare professionals who treat patients with hepatocellular carcinoma and biliary tract cancer.

Time and location

Thursday, March 09, 2023

6:00 PM - 7:00 PM Central Time (CT)

In-person

Private Event
Madison, Wisconsin

Agenda

  • Introduction and Overview
  • First-line Systemic Therapy for Advanced HCC: Current and Emerging Options
  • Second-line Therapy for Advanced HCC
  • Systemic Therapy Combinations for Early or Intermediate-Stage HCC: Current Evidence and Ongoing Trials
  • BTC: Current and Emerging Immunotherapy and Targeted Therapy Regimens
  • Audience Q&A

Location

Venue Name

Private Event

Address

Private Event
Madison, Wisconsin

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate current and emerging systemic therapies into the treatment of patients with hepatocellular carcinoma and biliary tract cancers.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate clinical data on the use of systemic treatment approaches for patients with early or intermediate-stage HCC
  • Plan optimal, individualized therapy approaches using immune checkpoint inhibitor-based regimens for patients with advanced or metastatic HCC, as clinically appropriate
  • Test tumors for biomarkers that can identify patients with hepatobiliary cancers suitable for targeted therapy
  • Develop strategies to identify and mitigate unique adverse events associated with immune checkpoint inhibitors and targeted therapies in patients with HCC or BTC

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-196-L01-P

Type of Activity: Knowledge

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Educational grants provided by AstraZeneca and Genentech, a member of the Roche Group

Program Learning Goal

The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate current and emerging systemic therapies into the treatment of patients with hepatocellular carcinoma and biliary tract cancers.

Contact Information

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.